Drug Type Antibody drug conjugate (ADC) |
Synonyms SGN CD47M |
Target |
Action inhibitors |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 17 Jul 2019 | |
Breast Cancer | Phase 1 | United States | 17 Jul 2019 | |
Colorectal Cancer | Phase 1 | United States | 17 Jul 2019 | |
Melanoma | Phase 1 | United States | 17 Jul 2019 | |
Non-Small Cell Lung Cancer | Phase 1 | United States | 17 Jul 2019 | |
Ovarian Cancer | Phase 1 | United States | 17 Jul 2019 | |
Pancreatic adenocarcinoma | Phase 1 | United States | 17 Jul 2019 | |
Soft Tissue Sarcoma | Phase 1 | United States | 17 Jul 2019 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | United States | 17 Jul 2019 | |
Stomach Cancer | Phase 1 | United States | 17 Jul 2019 |